Business
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
CARLSBAD, Calif., Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"CARLSBAD, Calif., Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting preclinical data on TYRA-300 during a poster session at the European Society for Medical Oncology (ESMO) 2022 Congress, being held in person September 9-13, 2022 in Paris, France. \n\"We believe the preclinical results being presented at the ESMO Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class,\" said Todd Harris, CEO of TYRA. \"These encouraging data support the advancement of TYRA-300 into the clinic, and we look forward to initiating our SURF301 Phase 1/2 study in the near term.\"\nDetails of the poster presentation are as follows:\nTitle: TYRA-300: FGFR3 selective and gatekeeper agnosticPresenter: Jacqueline StarrettDate: Monday, September 12, 2022Session: Developmental therapeuticsPresentation Number: 462P\nRegular abstracts will be published on the ESMO website on September 5, 2022. The poster presentation on TYRA-300 will be made available on the TYRA website under the \"For Investors\" section on September 12, 2022.\nAbout TYRA-300\nTYRA-300 is the Company's lead precision oncology program generated from TYRA's proprietary SNÅP drug discovery platform. TYRA-300 is an FGFR3-selective inhibitor designed to be agnostic to the gatekeeper mutation and has demonstrated less hyperphosphatemia mediated by FGFR1 inhibition than pan-FGFR inhibitors in preclinical models. In July 2022, the U.S. Food and Drug Administration (FDA) cleared TYRA to proceed with its Phase 1/2 SURF301 clinical study of TYRA-300 under its Investigational New Drug application (IND), in patients with metastatic urothelial carcinoma of the bladder and urinary tract. SURF301 is a two-part study designed to determine the optimal and maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300. \nAbout Tyra Biosciences\nTyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA's proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinemen...